Seattle-based Impel Neurpharma, the developer of technology to deliver drugs to the brain, said today it has secured a two-year, $750,000 grant from the U.S. Department of Defense. The company, a University of Washington spinout, previously got a $500,000 grant from the National Institutes of Health to support its method for delivering drugs through the upper nasal cavity, bypassing the blood-brain barrier, which limits the effectiveness of many neurological drugs. For more on Impel and its technology, check this profile from August 2008, when the company was getting going.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
